The U.S. Food & Drug Administration (FDA) is warning about an increased risk of a severe kidney complication known as acute interstitial nephritis associated with proton pump inhibitor (PPI) heartburn medications like Vimovo.
Free Confidential Lawsuit Evaluation: If you or a loved one was injured, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.
What is Vimovo?
Vimovo is a combination of esomeprazole, a PPI, and naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Esomeprazole works by decreasing the amount of acid the stomach makes, and naproxen reduces substances in the body that cause inflammation, pain and fever. Vimovo is used to treat the symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis when there is a high risk for stomach bleeding/ulcer.
Vimovo Nephritis Studies
Acute interstitial nephritis (AIN) is an increasingly reported side effect of proton pump inhibitor heartburn medications like Vimovo.
Esomeprazole was specifically linked to AIN in 2 reports published in the Medical Journal of Australia (MJA) in 2005. In both cases, the drug was found to be the “likely causative agent” associated with the condition, with the patients’ symptoms improving upon cessation.
Prior to the cases reported by MJA, Australia’s Adverse Drug Reactions Advisory Committee (ADRAC) had been notified of at least 4 cases of acute interstitial nephritis linked to esomeprazole, as well as 6 cases of acute renal failure and 2 cases of renal impairment. AstraZeneca, the manufacturer of esomeprazole, announced in 2004 that it was aware of at least 15 cases worldwide of AIN potentially associated with the drug, and at least 200 cases worldwide linked to omeprazole (the active ingredient in Prilosec and Losec).
FDA in December 2014 updated Vimovo warning labels with information about the increased risk of acute interstitial nephritis associated with use of the drug. The agency warned that AIN can occur at any time during treatment with the drug, and that Vimovo users experiencing accompanying symptoms should talk to their doctor immediately.
PPI-induced acute interstitial nephritis is often difficult to diagnose because symptoms are nonspecific and can mimic the original indications for which the PPI was prescribed. When they do present, however, symptoms of AIN may include:
- Blood in the urine
- Increased or decreased urine output
- Mental status changes (drowsiness, confusion, coma)
- Swelling of the body
- Weight gain
Acute interstitial nephritis may be diagnosed in PPI users with enlarged kidneys. The patient’s doctor will likely recommend discontinuing treatment with Vimovo and other other drugs that may be causing the condition. In most cases, AIN resolves within several months upon cessation of offending medications. However, nephritis can lead to chronic kidney disease (CKD) and end-stage renal failure if left untreated.
Do I Have a Vimovo Acute Interstitial Nephritis Lawsuit?
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Vimovo lawsuits. We are handling individual litigation nationwide and currently accepting new nephritis cases in all 50 states.
Free Confidential Case Evaluation: Again, if you developed acute interstitial nephritis from Vimovo, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.